Definition of p53 overexpression and its association with the clinicopathological features in luminal/HER2-negative breast cancer

Anticancer Research

Volumn 33, Issue 9, 2013, Pages 3891-3898

  Kikuchi, Shoichi ^a,b   Nishimura, Reiki ^a   Osako, Tomofumi ^a   Okumura, Yasuhiro ^a   Nishiyama, Yasuyuki ^a   Toyozumi, Yasuo ^a   Arima, Nobuyuki ^a  

^a KUMAMOTO CITY HOSPITAL   (Japan)

^b JSDF Kumamoto Hospital   (Japan)

Author keywords

Clinicopathological features; Immunohistochemistry; Luminal HER2 negative breast cancer; P53 cut off point; P53 overexpression; Prognostic factor

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; KI 67 ANTIGEN; PROGESTERONE RECEPTOR; PROTEIN P53; TRASTUZUMAB;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURGERY; CANCER SURVIVAL; CLINICAL FEATURE; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; SURGICAL PATIENT; TUMOR VOLUME;

CLINICOPATHOLOGICAL FEATURES; IMMUNOHISTOCHEMISTRY; LUMINAL/HER2-NEGATIVE BREAST CANCER; P53 CUT-OFF POINT; P53 OVEREXPRESSION; PROGNOSTIC FACTOR;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; KI-67 ANTIGEN; MIDDLE AGED; PROGNOSIS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RETROSPECTIVE STUDIES; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84884998663     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thürlimann B, Senn HJ; Panel members. Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol 22: 1736-1747, 2011.
2. Millar EK, Graham PH, McNeil CM, Browne L, O'Toole SA, Boulghourjian A, Kearsley JH, Papadatos G, Delaney G, Fox C, Nasser E, Capp A and Sutherland RL: Prediction of outcome of early ER+ breast cancer is improved using a biomarker panel, which includes Ki-67 and p53. Br J Cancer 105: 272-280, 2011.
3. Hasebe T, Iwasaki M, Akashi-Tanaka S, Hojo T, Shibata T, Sasajima Y, Kinoshita T and Tsuda H: p53 expression in tumorstromal fibroblasts forming and not forming fibrotic foci in invasive ductal carcinoma of the breast. Mod Pathol 23: 662-672, 2010.
4. Guarneri V, Barbieri E, Piacentini F, Giovannelli S, Ficarra G, Frassoldati A, Maiorana A, D'Amico R and Conte P: Predictive and prognostic role of p53 according to tumor phenotype in breast cancer patients treated with preop. erative chemotherapy: a single-institution analysis. Int J Biol Markers 25: 104-111, 2010.
5. Kim HS, Yom CK, Kim HJ, Lee JW, Sohn JH, Kim JH, Park YL and Ahn SH: Overexpression of p53 is correlated with poor outcome in premenopausal women with breast cancer treated with tamoxifen after chemotherapy. Breast Cancer Res Treat 121: 777-788, 2010.
6. Yamashita H, Toyama T, Nishio M, Ando Y, Hamaguchi M, Zhang Z, Kobayashi S, Fujii Y and Iwase H: p53 protein accumulation predicts resistance to endocrine therapy and decreased post-relapse survival in metastatic breast cancer. Breast Cancer Res 8: R48, 2006.
7. Berns EM, Foekens JA, Vossen R, Look MP, Devilee P, Henzen-Logmans SC, van Staveren IL, van Putten WL, Inganäs M, Meijer-van Gelder ME, Cornelisse C, Claassen CJ, Portengen H, Bakker B and Klijn JG: Complete sequencing of TP53 predicts poor response to systemic therapy of advanced breast cancer. Cancer Res 60: 2155-2162, 2000.
8. Kai K, Nishimura R, Arima N, Miyayama H and Iwase H: p53 expression status is a significant molecular marker in predicting the time to endocrine therapy failure in recurrent breast cancer: a cohort study. Int J Clin Oncol 11: 426-433, 2006.
9. Di Leo A, Tanner M, Desmedt C, Paesmans M, Cardoso F, Durbecq V, Chan S, Perren T, Aapro M, Sotiriou C, Piccart MJ, Larsimont D, Isola J; TAX 303 translational study team. p-53 gene mutations as a predictive marker in a population of advanced breast cancer patients randomly treated with doxorubicin or docetaxel in the context of a phase III clinical trial. Ann Oncol 18: 997-1003, 2007.
10. Kandioler-Eckersberger D, Ludwig C, Rudas M, Kappel S, Janschek E, Wenzel C, Schlagbauer-Wadl H, Mittlböck M, Gnant M, Steger G and Jakesz R: TP53 mutation and p53 overexpression for prediction of response to neoadjuvant treatment in breast cancer patients. Clin Cancer Res 6: 50-56, 2000.
11. Lara JF, Thor AD, Dressler LG, Broadwater G, Bleiweiss IJ, Edgerton S, Cowan D, Goldstein LJ, Martino S, Ingle JN, Henderson IC, Norton L, Winer EP, Hudis CA, Ellis MJ, Berry DA, Hayes DF; Cancer and Leukemia Group B. p53 Expression in node-positive breast cancer patients: results from the Cancer and Leukemia Group B 9344 Trial (159905). Clin Cancer Res 17: 5170-5178, 2011.
12. Cattoretti G, Rilke F, Andreola S, D'Amato L and Delia D: P53 expression in breast cancer. Int J Cancer 41: 178-183, 1988.
13. Bullock AN, Henckel J and Fersht AR: Quantitative analysis of residual folding and DNA binding in mutant p53 core domain: definition of mutant states for rescue in cancer therapy. Oncogene 19: 1245-1256, 2000.
14. Bullock AN and Fersht AR: Rescuing the function of mutant p53. Nat Rev Cancer 1: 68-76, 2001.
15. Rodrigues NR, Rowan A, Smith ME, Kerr IB, Bodmer WF, Gannon JV and Lane DP: p53 mutations in colorectal cancer. Proc Natl Acad Sci USA 87: 7555-7559, 1990.
16. Kaserer K, Schmaus J, Bethge U, Migschitz B, Fasching S, Walch A, Herbst F, Teleky B and Wrba F: Staining patterns of p53 immunohistochemistry and their biological significance in colorectal cancer. J Pathol 190: 450-456, 2000.
17. Tashima R, Nishimura R and Arima N: Evaluation of an optimal cut-off point for the Ki-67 index as a prognostic factor in primary breast cancer. CTRC-AACR SAN ANTONIO BREAST CANCER SYMPOSIUM. San Antonio. 2012.
18. Friedrichs K, Gluba S, Eidtmann H and Jonat W: Overexpression of p53 and prognosis in breast cancer. Cancer 72: 3641-3647, 1993.
19. Marks JR, Humphrey PA, Wu K, Berry D, Bandarenko N, Kerns BJ and Iglehart JD: Overexpression of p53 and HER-2/neu proteins as prognostic markers in early stage breast cancer. Ann Surg 219: 332-341, 1994.
20. Martinazzi M, Crivelli F, Zampatti C and Martinazzi S: Relationship between p53 expression and other prognostic factors in human breast carcinoma. An immunohistochemical study. Am J Clin Pathol 100: 213-217, 1993.
21. Coutant C, Rouzier R, Qi Y, Lehmann-Che J, Bianchini G, Iwamoto T, Hortobagyi GN, Symmans WF, Uzan S, Andre F, de Thé H and Pusztai L: Distinct p53 gene signatures are needed to predict prognosis and response to chemotherapy in ER-positive and ER-negative breast cancers. Clin Cancer Res 17: 2591-2601, 2011.
22. Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature 490: 61-70, 2012.
23. Muller PA, Vousden KH and Norman JC: p53 and its mutants in tumor cell migration and invasion. J Cell Biol 192: 209-218, 2011.